🚀 VC round data is live in beta, check it out!
Protara Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Protara Therapeutics and similar public comparables like Polaryx Therapeutics, Circio Holding, Foghorn Therapeutics, Dishman Carbogen Amics and more.
Protara Therapeutics Overview
About Protara Therapeutics
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Founded
2006
HQ
Employees
33
Website
Sectors
Financials (LTM)
EV
$116M
Protara Therapeutics Financials
Protara Therapeutics reported last 12-month revenue of — and negative EBITDA of ($70M).
In the same LTM period, Protara Therapeutics generated — in gross profit, ($70M) in EBITDA losses, and had net loss of ($64M).
Revenue (LTM)
Protara Therapeutics P&L
In the most recent fiscal year, Protara Therapeutics reported revenue of — and EBITDA of ($64M).
Protara Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($70M) | XXX | ($64M) | XXX | XXX | XXX |
| Net Profit | ($64M) | XXX | ($57M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Protara Therapeutics Stock Performance
Protara Therapeutics has current market cap of $268M, and enterprise value of $116M.
Market Cap Evolution
Protara Therapeutics' stock price is $4.96.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $116M | $268M | -6.4% | XXX | XXX | XXX | $-1.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProtara Therapeutics Valuation Multiples
Protara Therapeutics trades at (1.7x) EV/EBITDA.
Protara Therapeutics Financial Valuation Multiples
As of April 11, 2026, Protara Therapeutics has market cap of $268M and EV of $116M.
Equity research analysts estimate Protara Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Protara Therapeutics has a P/E ratio of (4.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $268M | XXX | $268M | XXX | XXX | XXX |
| EV (current) | $116M | XXX | $116M | XXX | XXX | XXX |
| EV/EBITDA | (1.7x) | XXX | (1.8x) | XXX | XXX | XXX |
| EV/EBIT | (1.7x) | XXX | (1.8x) | XXX | XXX | XXX |
| P/E | (4.2x) | XXX | (4.7x) | XXX | XXX | XXX |
| EV/FCF | (1.7x) | XXX | (2.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Protara Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Protara Therapeutics Margins & Growth Rates
Protara Therapeutics' revenue in the last fiscal year grew by —.
Protara Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.0M for the same period.
Protara Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 25% | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Protara Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Polaryx Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Circio Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Foghorn Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alector | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Protara Therapeutics M&A Activity
Protara Therapeutics acquired XXX companies to date.
Last acquisition by Protara Therapeutics was on XXXXXXXX, XXXXX. Protara Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Protara Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProtara Therapeutics Investment Activity
Protara Therapeutics invested in XXX companies to date.
Protara Therapeutics made its latest investment on XXXXXXXX, XXXXX. Protara Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Protara Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Protara Therapeutics
| When was Protara Therapeutics founded? | Protara Therapeutics was founded in 2006. |
| Where is Protara Therapeutics headquartered? | Protara Therapeutics is headquartered in United States. |
| How many employees does Protara Therapeutics have? | As of today, Protara Therapeutics has over 33 employees. |
| Who is the CEO of Protara Therapeutics? | Protara Therapeutics' CEO is Jesse Shefferman. |
| Is Protara Therapeutics publicly listed? | Yes, Protara Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Protara Therapeutics? | Protara Therapeutics trades under TARA ticker. |
| When did Protara Therapeutics go public? | Protara Therapeutics went public in 2020. |
| Who are competitors of Protara Therapeutics? | Protara Therapeutics main competitors are Polaryx Therapeutics, Circio Holding, Foghorn Therapeutics, Dishman Carbogen Amics. |
| What is the current market cap of Protara Therapeutics? | Protara Therapeutics' current market cap is $268M. |
| Is Protara Therapeutics profitable? | No, Protara Therapeutics is not profitable. |
| What is the current EBITDA of Protara Therapeutics? | Protara Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Protara Therapeutics? | Current EBITDA multiple of Protara Therapeutics is (1.7x). |
| What is the current FCF of Protara Therapeutics? | Protara Therapeutics' last 12 months FCF is ($69M). |
| What is the current EV/FCF multiple of Protara Therapeutics? | Current FCF multiple of Protara Therapeutics is (1.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.